Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 76,035 shares of the medical research company's stock after selling 1,909 shares during the period. California State Teachers Retirement System owned approximately 0.15% of Charles River Laboratories International worth $14,036,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Optiver Holding B.V. bought a new stake in Charles River Laboratories International in the fourth quarter worth $37,000. GeoWealth Management LLC increased its position in Charles River Laboratories International by 311.5% during the fourth quarter. GeoWealth Management LLC now owns 251 shares of the medical research company's stock valued at $46,000 after acquiring an additional 190 shares during the last quarter. Pilgrim Partners Asia Pte Ltd bought a new position in Charles River Laboratories International during the fourth quarter valued at $48,000. Tortoise Investment Management LLC increased its position in Charles River Laboratories International by 77.7% during the fourth quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock valued at $49,000 after acquiring an additional 115 shares during the last quarter. Finally, Huntington National Bank increased its position in Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after acquiring an additional 164 shares during the last quarter. Institutional investors own 98.91% of the company's stock.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the transaction, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is currently owned by insiders.

Charles River Laboratories International Stock Up 3.5%

Shares of CRL stock traded up $4.83 during mid-day trading on Wednesday, hitting $143.32. 849,402 shares of the stock traded hands, compared to its average volume of 995,086. The stock has a market cap of $7.04 billion, a P/E ratio of 955.47, a P/E/G ratio of 4.54 and a beta of 1.48. The stock's fifty day moving average is $127.93 and its two-hundred day moving average is $159.55. Charles River Laboratories International, Inc. has a 52-week low of $91.86 and a 52-week high of $254.15. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, beating the consensus estimate of $2.06 by $0.28. The business had revenue of $984.17 million during the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company's quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the firm posted $2.27 earnings per share. Equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price for the company in a research note on Wednesday, May 14th. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and boosted their target price for the company from $155.00 to $175.00 in a research note on Tuesday, March 4th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their target price for the company from $190.00 to $170.00 in a research note on Friday, March 21st. Evercore ISI raised shares of Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price for the company in a research note on Thursday, May 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research note on Thursday, February 20th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).